Early Innovation Awards
As a company committed to therapeutic progress to serve patient needs, Servier takes an open and collaborative approach to R&D at every stage of the drug development life cycle, including early-stage discovery – where we are proud to support the next generation of innovation.
Our awards recognize the aspiring life-science companies and entrepreneurs who are driving scientific innovation in areas of high unmet need, including hard-to-treat diseases in oncology, neuroscience and immuno-inflammation, as well as those pursuing research in translational medicine, drug development technologies and drug delivery platforms.
FAST Discovery Award: California Life Sciences
Servier is a proud FAST Track Partner of the California Life Sciences (CLS) FAST Advisory Program, designed to provide founders of disruptive innovative life science companies with a customized advisory program to perfect their business models, assess strategic focus, maximize IP and help develop a milestone and scale-up plan to exit.
Every year, Servier is looking for startups developing innovative approaches in the following discovery and early clinical areas of interest:
– Oncology: Cancer cell targeting (e.g., synthetic lethality, precision oncology) and immuno-oncology (e.g., tumor micro-environment, T-cell targeting)
– Neuroscience: Rare neurological disorders (e.g., familial Amyotrophic Lateral Sclerosis, genetically driven pediatric epilepsies) and sub-populations of neurodegenerative diseases
– Novel modality development strategies for small molecules, biologics (including bi-specifics, ADCs) and oligonucleotides (including ASOs), as well as targeted delivery strategies (e.g., tumor-specific, CNS delivery mechanisms)
– AI/ML data-driven platforms for drug design (including oligonucleotides and antibodies) and to support translational activities (target and biomarker identification)
Submissions typically open during the summer, check back here to apply for 2025. To learn more about FAST California, visit here.
LabCentral Golden Tickets: Cambridge, MA
Servier is a proud Gold sponsor of LabCentral, a premier shared laboratory space located in Cambridge, Massachusetts, designed as a launchpad for life science and biotech startups. Each year, Servier sponsors a contest to award one “Golden Ticket” to support and celebrate promising life-science companies and entrepreneurs. The winner of the “Golden Ticket” will receive a $50,000 credit towards space and services available at LabCentral 700 for use within a 13-month period. Servier will also provide access to its team of talented experts who can provide guidance and feedback to early-stage companies.
2025 Servier Golden Ticket Contest: LabCentral
Servier is pleased to open the call for applications for the 2025 Golden Ticket Contest to interested startups developing innovative approaches in the following discovery and early clinical areas of interest:
How to Apply:
To apply, submit a non-confidential pitch deck highlighting your innovative approach to advancing therapies for patients with high unmet needs through this form. All submissions will be reviewed. Three semi-finalists will be invited to a pitch event at LabCentral in Cambridge, MA, where the Golden Ticket winner will be announced!
Timelines:
Disclosures:
The winner of the “Golden Ticket” Contest shall receive a $50,000 credit towards space and services available at LabCentral 700 for use within a 13-month period, beginning upon receipt. Additional terms and conditions apply, subject to Servier and LabCentral’s discretion. All submissions shall be reviewed. Recipient shall not receive consideration in the form of cash. Recipients seeking access to, and discussions with, Servier employees in the form of guidance or feedback may be required to execute appropriate confidentiality agreements, at Servier’s discretion. If you have any questions, please direct them to GoldenTicket@servier.com. More information about the LabCentral Golden Ticket program can be found here.
Servier as a Partner-of-Choice
To see the types of partnerships the team is pursuing, please visit here.